EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, NRIX: Nurix Therapeutics Inc

12 Jun 26 15:59
LAST:

16.95

CHANGE:
 0.03		OPEN:
16.85		HIGH:
18.91		ASK:
0.00		VOLUME:
1.8M
CHG(%):
0.18		PREV:
16.98		LOW:
16.29		BID:
0.00		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
12 Jun 2617.1618.9116.8816.952.56M
11 Jun 2615.1917.1715.1516.984.03M
10 Jun 2615.8016.1215.1715.302.54M
09 Jun 2616.0016.9914.6715.646.67M
08 Jun 2616.7318.2015.3615.6421.07M
05 Jun 2615.3115.5814.2414.641.63M
04 Jun 2615.6715.9115.2615.281.58M
03 Jun 2616.3116.3415.4315.481.33M
02 Jun 2617.0217.2316.2916.371.05M
01 Jun 2617.7317.7316.8517.39851.6K

PROFILE

Name:Nurix Therapeutics Inc
About:Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase 1A clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1A clinical trials to treat immuno-oncology indications. It is also developing NX 0479/GS 6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.
Sector:Healthcare
Industry:Biotechnology
Address:1700 Owens Street, San Francisco, CA, United States, 94158
Website:https://www.nurixtx.com
CUSIP:67080M103
CIK:0001549595
ISIN:US67080M1036
FIGI:BBG00SDJ8M78

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-4.38 
Forward P/E:-5.26 
PEG Ratio:0.16 
Price to Sales:15.67 
Price to Book:3.01 
Profit Margin:-2.93 
Operating Margin:-11.58 
Return on Assets:-0.32 
Return on Equity:-0.65 
EPS Ratio:-3.05 
Revenue:83.69M 
Shares:103.41M 
Market Cap:1.753B 

TECHNICAL INDICATORS

MA5:16.105.3%
MA10:15.976.2%
MA20:16.403.4%
MA50:16.433.2%
MA100:16.264.2%
MA200:14.9213.6%
STO9:54.10
STO14:54.10
RSI14:45.88
WPR14:-25.96
MTM14:-0.43
ROC14:-0.02 
ATR:1.33 
Week High:18.9111.6%
Week Low:14.2419.0%
Month High:18.9111.6%
Month Low:14.2413.6%
Year High:22.5032.7%
Year Low:8.20106.8%
Volatility:4.22